Heat shock protein vaccines against glioblastoma: from bench to bedside

Leonel Ampie, Winward Choy, Jonathan B. Lamano, Shayan Fakurnejad, Orin Bloch*, Andrew T. Parsa

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

58 Scopus citations


Current adjuvant treatment regimens available for the treatment of glioblastoma are widely ineffective and offer a dismal prognosis. Advancements in conventional treatment strategies have only yielded modest improvements in overall survival. Immunotherapy remains a promising adjuvant in the treatment of GBM through eliciting tumor specific immune responses capable of producing sustained antitumor response while minimizing systemic toxicity. Heat shock proteins (HSP) function as intracellular chaperones and have been implicated in the activation of both innate and adaptive immune systems. Vaccines formulated from HSP-peptide complexes, derived from autologous tumor, have been applied to the field of immunotherapy for glioblastoma. The results from the phase I and II clinical trials have been promising. Here we review the role of HSP in cellular function and immunity, and its application in the treatment of glioblastoma.

Original languageEnglish (US)
Pages (from-to)441-448
Number of pages8
JournalJournal of Neuro-Oncology
Issue number3
StatePublished - Jul 23 2015


  • Clinical trial
  • Glioblastoma
  • Glioma
  • Heat shock protein
  • Immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Heat shock protein vaccines against glioblastoma: from bench to bedside'. Together they form a unique fingerprint.

Cite this